$0.13
+0.00 (+0.16%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where AZTR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 3 tracked-famous managers (JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal ToxicityNCT06830863Safety and tolerabilityRandomized · Quadruple-masked · Treatment | Phase 1/2 | Recruiting | Drug: ATR04-484, Vehicle | EGFR Inhibitor-associated Rash | 32 | 2027-01-15 | in 148 d | 2026-02-11 |
| Evaluation of Topical ATR12-351 in Adults With Netherton SyndromeNCT06137157Adverse eventsOpen-label · Treatment | Phase 1 | Completed | Drug: ATR12-351 | Netherton Syndrome | 6 | 2026-07-07actual | — | 2026-07-29 |
| Study to Evaluate the Safety of ATR-04NCT04731259Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), incidence of abnormal laboratory values, abnormal physical exams and abnormal vital signs.Randomized · Double-masked · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Business reasons. | Drug: ATR-04 · Other: Placebo | Epidermal Growth Factor, Papulopustular Rosacea | 0 | Jan 2026 | — | 2025-10-03 |
| Safety Study of AZT-04 for Cosmetic UseNCT03820076Safety and Tolerance: mean erythemaRandomized · Quadruple-masked · Other | Not applicable | Completed | Other: AZT-04 | Study of Three Doses of AZT-04 for Skin Appearance | 21 | 2019-01-21actual | — | 2020-07-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19